# TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

Source: https://onco.cc/trials/nct07074106/  
OnCo record `nct07074106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin in triple-negative breast cancer, run by D'Or Institute for Research and Education, now recruiting.

## Summary

TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC is a phase 2, interventional study registered as NCT07074106 by D'Or Institute for Research and Education, with a registry enrolment figure of 40 participants, started 2025-10-31 and due to reach its primary completion in 2027-07-01. Interventions recorded: Carboplatin and a Taxane. Conditions listed: Breast Cancer. Sites: Brazil. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: DespaTIL
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07074106
- Phase: 2
- Setting: DespaTIL Study: A Phase II Trial of De-escalated Neoadjuvant Chemotherapy for Early-Stage Triple-Negative Breast Cancer Guided by Tumor-Infiltrating Lymphocytes (TILs) and Radiologic Response
- Sponsor: D'Or Institute for Research and Education
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07074106: https://clinicaltrials.gov/study/NCT07074106

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07074106.json